Previous 10 | Next 10 |
home / stock / bovnf / bovnf news
LUND, SE / ACCESSWIRE / October 26, 2023 / BioInvent International (STO:BINV) "In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study. BI-1808 can potentially become a novel checkpoint inhibi...
LUND, SWEDEN / ACCESSWIRE / October 25, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2023 at 2:00 pm on Thursday October 26. The re...
LUND, SE / ACCESSWIRE / October 10, 2023 / BioInvent International (STO:BINV) The Phase 1 Part B will evaluate the combination of BT-001 and pembrolizumab in solid tumors, including melanoma. LUND, SWEDEN / ACCESSWIRE / October 10, 2023 / BioInvent International AB ("BioInvent") (Nasdaq Sto...
LUND, SE / ACCESSWIRE / September 27, 2023 / BioInvent International (STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it will hold two poster presentations on its anti-tumor n...
LUND, SWEDEN / ACCESSWIRE / September 22, 2023 / BioInvent International (STO:BINV) Strong interim safety data on BI-1808 as single agent reported in June 2023 Next data readout, from Phase 1 combination part of trial, to come in H1 2024 BioInvent International AB ("BioInvent") (Nasda...
LUND, SE / ACCESSWIRE / September 08, 2023 / BioInvent International (STO:BINV) First patient has been enrolled for treatment with subcutaneous BI-1206 in solid tumors Subcutaneous formulation will significantly improve convenience of dosing regimen BioInvent International AB ("BioIn...
2023-08-30 11:48:12 ET More on BioInvent International BioInvent potential cancer drug BI-1808 shows safety in interim phase 1/2a trial data Exelixis to pay BioInvent $25M upfront to discover antibodies for cancer therapies Earnings data for BioInvent International ...
LUND, SWEDEN / ACCESSWIRE / August 30, 2023 / BioInvent International (STO:BINV) "In the quarter, we had impressive early signals of efficacy in the Phase 1/2 trial of our lead drug candidate, the novel anti-FcgRIIB antibody BI-1206, in combination with rituximab in non-Hodgkin's lymphoma (NHL)....
Well-tolerated infusions, no dose limiting toxicities or serious adverse events Stable disease observed in six patients so far; efficacy to be further explored in Phase 2a LUND, SWEDEN / ACCESSWIRE / June 21, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInv...
LUND, SWEDEN / ACCESSWIRE / June 13, 2023 / BioInvent International (STO:BINV) Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and showcases the study design and status, and summarizes the early clinical results generated so far in...
News, Short Squeeze, Breakout and More Instantly...
Model-informed approach supporting dose selection and optimization of clinical development Confirming wide potential dose-range of BI-1808 in the continued clinical evaluation which already has shown promising single agent safety and efficacy Poster to be presented at PAGE 2024 to be ...
LUND, SWEDEN / ACCESSWIRE / June 24, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the China Nat...
BioInvent International (STO:BINV) Discussion on TNFR2 and FcyRIIB as promising targets in immuno-oncology on June 18, 2024 LUND, SWEDEN / ACCESSWIRE / May 30, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development...